Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espahol de Acromegalia, REA)

被引:280
作者
Mestrón, A
Webb, SM
Astorga, R
Benito, P
Catalá, M
Gaztambide, S
Gómez, JM
Halperín, I
Lucas-Morante, T
Moreno, B
Obiols, G
de Pablos, P
Páramo, C
Picó, A
Torres, E
Varela, C
Vázquez, JA
Zamora, J
Albareda, M
Gilabert, M
机构
[1] Autonomous Univ Barcelona, Hosp St Pau, Dept Endocrinol, Barcelona 08025, Spain
[2] Hosp Dos Maig, Dept Endocrinol, Barcelona, Spain
[3] Autonomous Univ Barcelona, Hosp St Pau, Dept Endocrinol, Barcelona, Spain
[4] Hosp Virgen Rocio, Dept Endocrinol, Seville, Spain
[5] Univ Cordoba, Reina Sofia Hosp, Dept Endocrinol, Cordoba, Spain
[6] Hosp Clin, Dept Endocrinol, Valencia, Spain
[7] Hosp Cruces, Dept Endocrinol, Bilbao, Spain
[8] Univ Barcelona, Bellvitge Hosp, Dept Endocrinol, Barcelona, Spain
[9] Univ Autonoma Madrid, Hosp Univ Puerta Hierro, Dept Endocrinol, Madrid, Spain
[10] Hosp Gregoria Maranon, Dept Endocrinol, Madrid, Spain
[11] Hosp Gen Univ Vall Hebron, Dept Endocrinol, Barcelona, Spain
[12] Hosp Juan Negrin, Dept Endocrinol, Las Palmas Gran Canaria, Spain
[13] Complexo Hosp Univ Xeral Cies, Dept Endocrinol, Vigo, Spain
[14] Miguel Hernandez Univ, Univ Hosp Alicante, Serv Endocrinol & Nutr, Alicante, Spain
[15] Hosp Clin San Cecilio, Dept Endocrinol, Granada, Spain
[16] Hosp Ramon & Cajal, Serv Endocrinol, E-28034 Madrid, Spain
[17] Remote Data Entry Syst SL, Barcelona, Spain
[18] Novartis Farmaceut, Oncol Unit, Dept Med, Barcelona, Spain
关键词
D O I
10.1530/eje.0.1510439
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To undertake a multicentre epidemiological study reflecting acromegaly in Spain. Design: Voluntary reporting of data on patients with acromegaly to an online database, by the managing physician. Methods: Data on demographics, diagnosis, estimated date of initial symptoms and diagnosis, pituitary imaging, visual fields, GH and IGF-1 concentrations (requested locally), medical, radiotherapy and neurosurgical treatments, morbidity and mortality were collected. Results: Data were included for 1219 patients (60.8% women) with a mean age at diagnosis of 45 years (s.D. 14 years). Reporting was maximal in 1997 (2.1 cases per million inhabitants (c.p.m.) per year); prevalence was globally 36 c.p.m., but varied between 15.7 and 75.8 c.p.m. in different regions. Of 1196 pituitary tumours, most were macroadenomas (73%); 81% of these patients underwent surgery, 45% received radiotherapy and 651% were given medical treatment (somatostatin analogues in 68.3% and dopamine agonists in 31.4%). Cures (GH values (basal or after an oral glucose tolerance test) < 2 ng/ml, normal IGF-I, or both) were observed in 40.3% after surgery and 28.2% after radiotherapy. Hypertension (39.1%), diabetes mellitus (37.6%), hypopituitarism (25.7%), goitre (22.4%), carpal tunnel syndrome (18.7%) and sleep apnoea (13.2%) were reported as most frequent morbidities; 6.8% of the patients had cancer (breast in 3.1% of the women and colon in 1. 2 % of the cohort). Fifty-six patients died at a mean age of 60 years (S.D). 14 years), most commonly of a cardiovascular cause (39.4%); mortality was greater in patients given radiotherapy (hazard ratio 2.29: 95% confidence interval 1.03 to 5.08; P = 0.026), and in those in whom GH and lGF-1 concentrations were never normal (P < 0.001). Conclusions: This acromegaly registry offers a realistic overview of the epidemiological characteristics, treatment outcome and morbidity of acromegaly in Spain. As active disease and treatment with radiotherapy are associated with an increase in mortality, efforts to control the disease early are desirable.
引用
收藏
页码:439 / 446
页数:8
相关论文
共 41 条
[1]  
Ahmed S, 1999, CLIN ENDOCRINOL, V50, P561
[2]   EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION [J].
ALEXANDER, L ;
APPLETON, D ;
HALL, R ;
ROSS, WM ;
WILKINSON, R .
CLINICAL ENDOCRINOLOGY, 1980, 12 (01) :71-79
[3]   Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly [J].
Ayuk, J ;
Clayton, RN ;
Holder, G ;
Sheppard, MC ;
Stewart, PM ;
Bates, AS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) :1613-1617
[4]  
BARCELO B, 1983, MED CLIN-BARCELONA, V80, P735
[5]  
BATES AS, 1993, Q J MED, V86, P293
[6]   Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly [J].
Beauregard, C ;
Truong, U ;
Hardy, J ;
Serri, O .
CLINICAL ENDOCRINOLOGY, 2003, 58 (01) :86-91
[7]  
BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327
[8]   Ten-year follow-up results of transsphenoidal microsurgery in acromegaly [J].
Biermasz, NR ;
Van Dulken, H ;
Roelfsema, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) :4596-4602
[9]   Pathogenesis and prevalence of hypertension in acromegaly [J].
Bondanelli M. ;
Ambrosio M.R. ;
degli Uberti E.C. .
Pituitary, 2001, 4 (4) :239-249
[10]   Pituitary surgery for acromegaly - Should be done by specialists [J].
Clayton, RN ;
Stewart, PM ;
Shalet, SM ;
Wass, JAH .
BRITISH MEDICAL JOURNAL, 1999, 319 (7210) :588-589